Korean J Pediatr Hematol Oncol.
2003 Apr;10(1):72-81.
Loss of Heterozygosity Analysis of Chromosome 17p13.1-13.3 and Its Correlation with Clinical Outcome in Medulloblastomas
- Affiliations
-
- 1Department of Pediatrics, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 2Department of Neurosurgery, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 3Department of Neurosurgery, Laboratory of Neuro-oncology, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. bkcho@snu.ac.kr
- 4Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
Abstract
- PURPOSE
Cytogenetic studies molecular genetic studies, including loss of heterozygosity (LOH) studies, have shown that deletions on the short arm of chromosome 17 (17p) distal to TP53 locus are the most common genetic events in medulloblastoma, and that these occur in 30 to 50% of medulloblastomas. We examined the occurrences and frequencies of allelic deletions on chromosome 17p13.1-13.3 by LOH analysis to investigate the possible involvement of 17p13.1-13.3 in medulloblastoma development. We also performed survival analysis to determine whether LOH analysis of 17p13.1-13.3 can be used to predict prognosis in medulloblastoma. METHOD: LOH was analyzed by polymerase chain reaction (PCR) on chromosome 17p13.1-13.3 using 3 microsatellite markers, TP53 on 17p13.1, D17S796 on 17p13.1-13.2 and D17S1574 on 17p13.3, in 17 medulloblastoma DNAs extracted from archival tissue specimens (cases 1~15) or fresh frozen tissue specimens (cases 16 and 17). RESULTS: Allelic deletions were detected in 5 of 17 informative cases (29%) on TP53, 8 of 17 informative cases (47%) on D17S796, and 4 of 17 informative cases (24%) on D17S1574. Overall, 9 of 17 cases (53%) showed LOH on chromosome 17p13.1-13.3. The 5-year progression free survival (PFS) and 5-year overall survival (OS) rates were identical (59%). The 5-year PFS for 9 medulloblastoma patients with LOH on 17p13.1-13.3 was 56%, and the 5-year PFS for 8 medulloblastoma patients without LOH on 17p13.1-13.3 was 63%. In our survival analysis, we did not find a significant association between survival and LOH on 17p13.1-13.3. CONCLUSION: Our results support the notion that deletions of chromosome 17p13.1-13.3 may be involved in the pathogenesis of medulloblastoma. From survival analysis, we conclude that LOH on chromosome 17p13.1-13.3 may not be a significant predictor of prognosis in medulloblastoma.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Loss of Heterozygosity on Chromosome 9p21, 17p13 and 3p in Human Astrocytic Tumor
- Loss of Heterozygosity at 1p, 7q, 17p, and 22q in Meningiomas
- Loss of Heterozygosity of Chromosome 17p13 and p53 Expression in Invasive Ductal Carcinomas
- Loss of Heterozygosity Studies on Chromosome 9, 22 and 17p in 12 Various Pediatric Brain Tumors
- Molecular Genetic Study on Human Meningiomas:Loss of Heterozygosity on Chromosome 22
